Name of the largest	CDT Houters		art undated or	15 10.04						
Name of the Issuer:	GPT Healthcare Limited	L	ast updated on	15-Nov-24						
1 Type of Issue (IPO / FPO)	IPO									
2 Issue Size (Rs. Cr)	525.14									
- Fresh Issue Size (Rs. Cr)	40.00									
Offer for Sale Component (Rs. Cr)     Source: Final Post Issue Report dated March 5, 2024	485.14									
Source: Pinar Post Issue Report dated Internitio, 2024										
3 Grade of issue along with name of the rating agency										
Name	Not Applicable									
Grade	Not Applicable									
4 Subscription Level (Number of times) Source: Final Post Issue Report dated March 5, 2024	6.2600*									
*The above figure is after technical rejections, multiple or du	plicate bids and bids not banked/returned									
5 QIB Holding (as a % of outstanding capital) as disclose	ed to stock exchanges									
Particulars	%									
(i) allotment in the issue	17.20%									
(ii) at the end of the 1st Quarter immediately after the listing issue (February 29, 2024)										
<ul> <li>(ii) at the end of 1st FY (March 31, 2024)<sup>#</sup></li> <li>(iv) at the end of 2nd FY (March 31, 2025)<sup>*</sup></li> </ul>	12.81% Not Available									
(V) at the end of 2nd FY (March 31, 2025)* (v) at the end of 3rd FY (March 31, 2026)*	Not Available									
"Period not completed " Given that the Company was listed on Eeb 29, 2024, the di	ta is presented for the pariod k-similar	b 29 2024								
Given that the Company was listed on Feb 29, 2024, the difference of Financials of the issuer	ne as presented for the period beginning on Fe	w nd, 2024								
			(In Rs. Crore)							
Parameters	1st FY (March 31, 2024)	2nd FY (March 31, 2025)*	3rd FY (March 31, 2026)*							
Income from operations Net Profit for the period	400.19 47.77	Not Available Not Available	Not Available Not Available							
Paid-up equity share capital	82.06	Not Available	Not Available							
Reserves excluding revaluation reserves *Period not completed	1,364.35	Not Available	Not Available							
7 Trading Status in the scrip of the issuer										
Company's Equity Shares are listed on both the BSE Limited The Shares have not been suspended or delisted.	and NSE.									
Particulars	Status									
(i) at the end of 1st FY (March 31, 2024)	Frequently Traded									
(ii) at the end of 2nd FY (March 31, 2025)*	Not Available									
(ii) at the end of 3rd FY (March 31, 2026)* *Period not completed	Not Available									
8 Change in Directors of issuer from the disclosures in	the offer document									
Destioniese	New of the Providence	Annalated (C								
Particulars (i) at the end of 1st FY (March 31, 2024)	Name of the Director a) Mr. Dwarka Prasad Tantia	Appointed / Resigned								
(ii) at the end of 2nd FY (March 31, 2025)**	b) Mr. Anurag Tantia Not Available	Not Available								
(ii) at the end of 3rd FY (March 31, 2026)**	Not Available	Not Available								
Source: Stock Exchange Filings **Period not completed										
9 Status of implementation of project/commencement of	f commercial production									
(i) as disclosed in the offer document	Not applicable									
(ii) Actual implementation	Not applicable									
(ii) Reasons for delay in implementation, if any	Not applicable									
10 Status of utilization of issue proceeds										
(i) as disclosed in the offer document			(In Rs. Crore)							
Particulars	Amount proposed to be funded from Net Proceeds	Estimated Deployment (Financial Year 2024)	Estimated Deployment (Financial Year 2025)							
Repayment or prepayment, in full or in part, of all or a portion	nof		(Financial Year 2025)							
certain outstanding borrowings availed by our Company from and financial institutions General Corporate Purposes	n banks 30.00 7.52	20.00	3.00							
Source: Prospectus dated February 26, 2024										
(ii) Actual utilization	(In Rs. Crore)									
Particulars Repayment or prepayment, in full or in part, of all or a portion certain autotaction borrowings, availed by our Company free	As of March 31. 2024									
certain outstanding borrowings availed by our Company from and financial institutions General Corporate Purposes # Source: Stock Exchange Intimation of statement of devia										
# Source: Stock Exchange Intimation of statement of devia (ii) Reasons for deviation, if any	tion/variation dated May 21, 2024 Not applicable									
, -y	opproved MRE									
11 Comments of monitoring agency, if applicable"										
(a) Comments on use of funds										
(b) Comments on deviation, if any, in the use of proceeds of from the objects stated in the offer document	The opposite									
(c) Any other reservations expressed by the monitoring age the end use of funds <sup>a</sup> Monitoring Agency is not applicable since the fresh issue										
normaring Agency is not applicable since the fresh issue	www.rs.resis exert HS. TUU CRITES									
12 Pricing Data										_
Issue Price (Rs.):	186 BSE									
Designated Stock Exchange: Listing Date:	BSE 29-Feb-24									
	At close of	At close of 30th calendar	At close of 90th calendar day	As at the end of 1st FY after	r the listing of the issue	As at the end of 2nd	FY after the listing of the issue	As at the end of	3rd FY after the listing of the iss	sue
Price parameters	It close of listing day (Feb 29, 2024)	day from listing day (Mar 29, 2024) <sup>(107)</sup>	from listing day May 28, 2024) <sup>(2)</sup>	(March 31, 2 Closing price	igh Low	Classical and an	rch 31, 2025) <sup>(2)(1)</sup> High Low	Classica salas	March 31, 2026) <sup>(2) (4)</sup> High Lor (during the EX) (during t	pw
Market Price on Designated Stock Exchange BSE SENSEX	200.75 72,500.30	176.45 73,651.35	147.55 75,170.45	(durin 176.45 73.651.35	219.70 (during the FY) 219.70 139.6 74,245.17 71,674.4	0 Not available	during the FY) (during the FY) Not available Not available Not available Not available	ble Not available	(during the FY) (during t Not available N Not available N	Not availa Not availa
BSE HEALTHCARE® Note:	35,079.32	73,651.35 35,052.84	35,562.18	35,052.84	74,245.37 71,674.4 35,342.21 33,389.2	9 Not available	Not available Not availe Not available Not availe	ible Not available ible Not available	Not available Not available Not	Not availa
<ol> <li>30th calendar day shall be taken as listing date plus 29 c</li> <li>90th calendar day shall be taken as listing date plus 89 c</li> </ol>	alendar days. alendar days. Since 90th calendar day is a Sar	turday, the next trading day is con	sidered.							
<ul><li>(3) High and Low based on intra day prices.</li><li>(4) Pricing data not disclosed as the relevant fiscal year and</li></ul>										
(5) BSE HEALTHCARE index represents the relevant sector (6) Given that the Company was listed on Feb 29, 2024, the	ral index	Feb 29, 2024								
(7) Incase of reporting date failing on a trading holiday, value			dered							

## 13 Basis for Issue Price

Accounting ratio		As disclosed in the offer document <sup>(1)</sup>	1st FY (March 31, 2024)	2nd FY (March 31, 2025)*	3rd FY (March 31, 2026)*
	Issuer:				
	Basic	4.88	43.29	Not Available	Not Availa
	Peer Group:				
	Global Health Limited	12.58	52.04	Not Available	Not Availa
	Krishna Institute of Medical	42.03	29.41	Not Available	Not Availal
EPS	Sciences Limited Jupiter Life Line Hospitals				
	Limited Yatharth Hospital & Trauma	13.95	28.65	Not Available	Not Availa
	Care Services Limited	10.09	14.46	Not Available	Not Availa
	Kovai Medical Center & Hospital Limited	105.80	164.25	Not Available	Not Availa
	Shalby Limited	6.31	9.67	Not Available	Not Availa
	Industry Avg:	Not Applicable	Not Applicable	Not Applicable	Not Applicat
	Issuer:				
	Basic	NA	9.26	Not Available	Not Availa
	Peer Group:				
	Global Health Limited	90.29	17.58	Not Available	Not Availa
	Krishna Institute of Medical Sciences Limited	49.51	69.98	Not Available	Not Availa
P/E	Jupiter Life Line Hospitals Limited	81.73	41.81	Not Available	Not Availa
	Yatharth Hospital & Trauma Care Services Limited	37.66	28.86	Not Available	Not Availa
	Kovai Medical Center &	29.93	22.78	Not Available	Not Availa
	Hospital Limited Shalby Limited	49.01	24.75	Not Available	Not Availal
	Industry Avg:	56.36	34.29	Not Applicable	Not Applicat
	issuer:	23.77	16.70	Not Available	Not Availa
	Peer Group:	20.11	10.70	No. Available	HCC Artista
	Global Health Limited	13.56	5.15	Not Available	Not Availal
RolWV (%)	Krishna Institute of Medical	20.35	12.61	Not Available	Not Availal
	Sciences Limited Jupiter Life Line Hospitals				
	Limited Yatharth Hospital & Trauma	19.94	15.11	Not Available	Not Availa
	Care Services Limited Koval Medical Center &	36.06	17.94	Not Available	Not Availa
	Hospital Limited	16.11	20.23	Not Available	Not Availa
	Shalby Limited	7.33	14.90	Not Available	Not Availab
	Industry Avg:	Not Applicable	Not Applicable	Not Applicable	Not Applicab
	Issuer:	20.54	230.74	Not Available	Not Availab
	Peer Group:				
	Global Health Limited	89.65	326.88	Not Available	Not Availa
	Krishna Institute of Medical Sciences Limited	206.47	233.31	Not Available	Not Availa
	Jupiter Life Line Hospitals Limited	64.70	178.16	Not Available	Not Availa
	Yatharth Hospital & Trauma Gare Services Limited	27.84	101.78	Not Available	Not Availal
	Kovai Medical Center & Hospital Limited	656.65	815.17	Not Available	Not Availa
	Shaby Limited	85.54	98.90	Not Available	Not Availa
	Industry Avg:	Not Applicable	Not Applicable	Not Applicable	Not Applical

Notes: (1) Sourced from Prospectus dated Feb 26, 2024. "Period not over

"Netroit not over Key ratios for the Company for the three flical years stated above shall be calculated as follows: (I) (EPS (Rk) is hord after that and thusbe to equily shareholders for the year divided by Vieghtsd average number of Equily Shares outstanding during the year / period (II) (E) - Couldy Muhat Drive and Hallwand Hace year and boyond (ER) (III) (RAW) - Rear unit with the Try and an approximation and the try and the try and the could be company divided by networth excluding non controlling interest (b) NAV year share - NAV is compated as net worth divided by number of equily shares outstanding.

## 14 Any other material information

search least least in beach specing receivangs     19 March 2024     24,000 There of BAC and a charged frequencial specing is part of the specing for BAC and Least 1, 2021     24,000 There of BAC and a frequencial specing part of the specing of the specing head of thead of thead o	Date of disclosure to Designated Stock Exchange	Announcement
1 a Holi, Anda         - Appointent of Mr. Undel Graph and Grappic 200 and to be consistent at BMP and J. April. 1, 2024.           19 Bach 2024         Decisions for the monoid per 2023 4. The Company is person the monoid on the period per 2023 4. The Company is person the monoid and the period period.           19 Bach 2024         Decisions for the formal per 2023 4. The Company is person the monoid one of the part of period.           19 Bach 2024         Decisions for the of the different advectories in the set of the period.           19 Bach 2024         Decisions for the of the different advectories.           19 Bach 2024         Record thesis to find the set of the part of period.           19 Bach 2024         Record thesis to find the set of the part of period period.           19 Bach 2024         Record thesis to find the set of the part of period.           19 Bach 2024         Part advectories.         Record thesis to find the set of the part of period.           19 Bach 2024         Part advectories.         Record thesis to find the set of the part of period.           19 Bach 2024         Part advectories.         Record thesis to find the set of the part of period.           19 Bach 2024         Part advectories.         Record the set of the part of period.           19 Aar 2024         Part advectories.         Record the set of the part of period.           19 Aar 2024         Part advectories.         Record advectories.         Record advectories	17 March 2024	stock of inventory, cash and other assets were found to be duly recorded and no unaccounted cash or transactions have been found by the authorities. The
19 March 2024 to the functionary accession of the donated method to the submit oblered t	19 March 2024	<ul> <li>Approval of unaudited financial results along with Limited Review Report for the quarter and nine months ended Dec 31, 2023</li> <li>Appointment of Mr. Vishal Goyal as Group COO and to be considered as SMP w.o.f. April 1, 2024</li> </ul>
19 March 2024         -March 2007           19 March 2024         Decomptions on the fight addres to read with the of the SEE (Lating Chapteria and Dicksous Requirements) Regulations, 2015, Investion           19 March 2024         Decomptions on the GPD 2024 association of GBD 2024 and provide Dicksous Requirements) Regulations, 2015 association of GBD 2024 and provide Dicksous Requirements (Lating Chapteria and Dicksous Requirements) Regulations, 2015 association Processing Company           18 April 2024         Parameter Regulations (Lating Chapteria and Dicksous Requirements) Regulations, 2015 association Processing Company           18 April 2024         Parameter Regulations (Li) (Li) on SEE (Li) (Ling Chapterias and Dicksous Requirements) Regulations, 2015 association Processing Company           18 April 2024         Parameter Regulations (Li) on SEE (Li) (Ling Chapterias and Dicksous Requirements) Regulations, 2016 association Processing Company           19 April 2024         Parameter Regulations, 2016 association Processing Company           19 April 2024         Parameter Regulations, 2016 association Processing Company           10 April 2024         Parameter Regulation, 2016 association Processing Company           10 April 2024         Regulation, 2016 association and Dicksous Regularismany (Li) association and April 2024 and Company a	19 March 2024	for the financial year 2023-24. The Company is expecting to pay the interim dividend to the shareholders on or before April 17, 2024. The Record Date for the purpo
Built Study         Presentation to GRP24 was automated for sparsing loop is parsed packed, and twentom.         Presentation to GRP24 was automated for sparsing special resource loop.           Balance 2024         Repert Data Mark 2024         Repert Data Mark 2024         Repert Data Mark 2024           Balance 2024         Repert Data Mark 2024         Repert Data Mark 2024         Repert Data Mark 2024           Balance 2024         Repert Data Mark 2024         Repert Data Mark 2024         Repert Data Mark 2024           Company of Data Mark 2024         Parsenet to Regulation 4010 A (10) of the SEB IL ASIDE Chapters and Dackmark Regulations. 2015 saund by Practicing Company Status 2014 of Repert Data Mark 2014 and Rep Practicing Company (Encompany Data Mark 2014 and Rep Practicing Company (Encompany Data Mark 2014 and Rep Practicing Company Status 2014 and Repert Data Mark 2014 and Rep Practicing Company (Encompany Data Mark 2014 and Rep Practicing Company (Encompany Data Mark 2014 and Rep Practicing Company Status 2014 and Repert Data Mark 2014 and Rep Practicing Company (Encompany Data Mark 2014 and Rep Practicing Company Status 2014 and Repert Data Mark 2014 and Rep Practicing Company (Encompany Data Mark 2014 and Repert Mark 2014 and Repert Data Mark 2014 and Repert Repert Data Mark 2014 and Repert Repert Data Mark 2014 and Repert Repert Repert Repert Repert Repert Repert Repert Repert	19 March 2024	- Mr. Anurag Tantia - Mrs. Kriti Tantia
Particulated below for printing speciel resolution for continuation of M. Daniha Passad Tankia as Chairman and Whether Director of the Company after statistic of 37 years. Parameterit is Regulation 30(1) 4 (10) of the SEII (Lating Chargingtons and Disclosure Regularements) Regulations. 2015 assurd by Practicing Company Bacterity for the year and edult of 10(1) of the SEII (Lating Chargingtons and Disclosure Regularements) Regulations. 2015 assurd by Practicing Company Bacterity for the year and edult of 10(1) of the SEII (Lating Chargingtons and Disclosure Regularements) Regulations. 2015 assurd by Practicing Company Bacterity of the year and edult of 10(1) of the SEII (Lating Chargingtons and the Disclosure Steppen stress of the April 2024 Parameter is SEII-ICODICAL DESEII-ICODICAL PROFENDING (Lating Lating Chargingtons and The April April 2024 Parameter is Regulation 300 and with Print Ard Schwade 1 & Discrements Bacteria Intel (Lating Chargingtons and Disclosure Regulations and Discrements) Resource and Chargington and the Print Ard Schwade 1 & Discrements Bacteria Parameter is Regulation 300 and with Print Ard Schwade 1 & Discrements Bacteria Intel (Lating Chargingtons and Discrements) Resource and Regulation 300 and and the Print Ard Schwade 1 & Discrements and Discrements and Discrements and Discrements and Discrements and Discrements Prints Lintel and exclosure Interprint Prints Lintel Application Interprint Prints Lintel Application Interprint Prints Lintel an	19 March 2024	
and model         the age of To years           10. Applicable         Persuest to Regulation (SU) (a) (10) of the SEB (Listing Collaptions and Disclose Requirements) Regulation (SU) (a) (10) of the SEB (Listing Collaptions and Disclose Requirements) Regulation (SU) (SU) (SU) (SU) (SU) (SU) (SU) (SU)	19 March 2024	Record Date for Payment of Divident revised to April 02, 204 from April 01, 2024
In Min. Audio         Besteries for the gate reduct flace, h. 1, 2024           In Min. 2024         Bill Chrosoft In Sell Biol Chrosoft In Sell Chroseft In Sell Chrosoft In Sell Chrosoft In Sell Chro	09 April 2024	Postal Balot Notice for passing special resolution for continuation of Mr. Dwarika Prasad Tantia as Chairman and Wholetime Director of the Company after attaining the age of 75 years
6 April 2024         Company does not fail under "Lang Company" (C) catagory as per the framework provide in Fey and Endong House) Threads and the fail of the Security as per the framework provide in Fey and Theorem Security (C) catagory as per the framework provide in Fey and Theorem Security (C) catagory as per the framework provide in Fey and Theorem Security (C) catagory as per the fail theorem Security (C) catagory (C)	16 April 2024	Pursuant to Regulation 40(9) & (10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 issued by Practicing Company Secretary for the year ended March 31, 2024
25. April 2024     Regulations, 2016 (Linking Regulations, 2) with the inform your but D. Butts Challing-Relativity, 100 (Relativity), 2017, 4000 (Relativity), 4000 (Relativity), 4000 (Relativity), 4000 (Relativity), 400	16 April 2024	In terms of SEBI Circular No. SEBIHODDHS/CIR/P2018/144 adad November 26, 2018 with regard to fund raising by issuence of debt securities by large entities, Company does not fail under "Large Corporate" (LC) category as per the finamework provided in the advorsatid circular. Therefore, the requirement of filing the initial disclosure and annual disclosure in Annexures A and B1 & B2 trespectively to the advorsation (LC) received news not area.
April 2024         Corpusy of Corpus April 2024         Corpusy of Corpus April 2024         Corpusy of Corpus April 2024           April 2024         The Corpus April 2024         The Corpus April 2024         The Corpus April 2024         The Corpus April 2024           April 2024         The Corpus April 2024         The Corpus April 2024         The Corpus April 2024         The Corpus April 2024           April 2024         Corpus April 2024         Corpus April 2024         The Corpus April 2024         The Corpus April 2024         The Corpus April 2024         Corpus April 2024         The Corpus A	25 April 2024	Regulations, 2015 ("Listing Regulations"), we wish to inform you that Dr. Bharbi Chattopadhayay, Chief Operating Officer of our Agartala Hospital part of the Senior
Othery Stock         Vehicy Reads & Schemister of Schemisters Report for Possibilities for continuation of Mr. Dearking Presad Texts as Chairman and Whells Time Director of the Company systematicity. Exception Possibilities & Possibilitis & Possibilitis & Possibilities & Possibilities & Possibilitis &	25 April 2024	Company Le GPT Healthcare Limited. Please be informed that our Company has further entered into Lease Agreement with Sun and Sun Inframetric Private Limited and Mosaic Infraventure Private Limit
Open by constraining the age of TS pass i           Value 2024         Company schedules of the Board of Decision of the Company is schedule to be held on Tunsday, May 21, 2024 at the Registered Office of the Company is schedule to be held on Tunsday, May 21, 2024 at the Registered Office of the Company is schedule to be held on Tunsday, May 21, 2024 at the Registered Office of the Company is schedule to be held on Tunsday, May 21, 2024 at the Registered Office of the Company is schedule to be held on Tunsday, May 21, 2024 at the Registered Office of the Company is schedule to be held on Tunsday, May 21, 2024 at the Registered Office of the Company is schedule to be held on Tunsday, May 21, 2024 at the Registered Office of the Company is schedule to the Advance Registered Office of the Company is schedule to the Advance Registered Office of the Company is schedule to the Advance Registered Office of the Company is schedule to the Advance Registered Office of the Company is schedule to the Advance Registered Office of the Company is schedule at the Register Office of the Company is schedule at the Register Office of the Company is schedule at the Registered Office of the Registered Office of the Company is schedule at the Registered Office of the Registered Office office office of the Registered Office of the Registered Office offi	26 April 2024	The CIN of the Company has changed from U70101WB1989PLC047402 to L70101WB1989PLC047402 by the Registrar of Companies, Kolkata, West Bengal
14 May 2024         Corputy, Ister Sill, is consider and approve biolong materia:         is the Audior Franceial Result on Support Network Sill Standards and Sill Standardstand Sill Standards And Sill Standard Standards and Sill Standard	10 May 2024	
<ul> <li>b) Declaration of manufact option by statutory, subtris in ther Addres Stepper on the annual analysis in the statutories interval interval</li></ul>	14 May 2024	Company, Inter-alia, to consider and approve following matters: a) the Audited Financial Results along with Report of the Statutory Auditors thereon of the Company for the 4th quarter and year ended on March 31, 2024
22 May 2024     CRCCFDCM0027019 dates/february, 8, 2016 issued by Securities and Exchange Board of Inda read-with Regulation 24A of the SEBI (Listing Obligations and Discourse Regulations, 2015       14 Jane 2024     Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Mitmation - Please find enclosed herewith infimition for Investor meet on June 19, 2024.       20 June 2024     Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Mitmation - Please find enclosed herewith infimition for Investor meet on June 19, 2024.       20 June 2024     Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Mitmation - Please find enclosed herewith infimition for Investor meet on June 19, 2024.       20 June 2024     Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Mitmation - Please find enclosed herewith infimition for Investor meet on June 19, 2024.       26 June 2024     Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Mitmation - Please find enclosed herewith infimition for Investor meet on June 19, 2024.       26 June 2024     Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Mitmation - Please find enclosed herewith infimition for Investor meet on June 19, 2024.	21 May 2024	<ol> <li>Declaration of unmodified optical hystaktory auditors in their Auditors Report on the annual auditor statisticities (Inscript Heeg audit and year ended March 11, 2024)</li> <li>Alexonmended Fried Divided of 15% La Rs. 1.5 particle and March 20, 2024 (Steps) (March 20, 2024)</li> <li>Alexonmended Fried Divided of 15% La Rs. 1.5 particle and year on the lace value of Rs. 10 each for the function year ended March 11, 2024</li> <li>Pravator R Bardon 24, 2014 (Statistic) Optigations and Dividence Requirements, 2015, 84 Response Orthogram and Statistics and Statistis and Statistics and Statistics and Statistics and Statistic</li></ol>
20 June 2024 Announcement under Regulation 30 (L.DDR)-Analyst / Investor Mest- Hismation - Please find enclosed herewith indimation for investor meet on June 28, 2024. 25 June 2024 Announcement under Regulation 30 (L.DDR)-Analyst / Investor Mest- Hismation - Please find enclosed herewith copies of New Paper Publication partaining to Information or 30th Annual General Meeting of the Company.	23 May 2024	CIR/CFD/CMDI/27/2019 dated February 8, 2019 issued by Securities and Exchange Board of India read with Regulation 24A of the SEBI (Listing Obligations and
Annoancement under Regulation 30 (LODR)-Newspaper Publication - Please find enclosed herewith copies of News Paper Publication pertaining to information or 30th Annual General Meeting of the Company.	14 June 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please find enclosed herewith intimation for investor meet on June 19, 2024.
cs. June 2004 35th Annual General Meeting of the Company.	20 June 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please find enclosed herewith intimation for investor meet on June 28, 2024.
25 June 2024 Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (As Amended)	25 June 2024	Announcement under Regulation 30 (LODR)-Newspaper Publication - Please find enclosed herewith copies of News Paper Publication pertaining to information on 35th Annual General Meeting of the Company.
	25 June 2024	Intimation Under Regulation 30 Of The SEBI (Listing Oblgations And Disclosure Requirements) Regulations, 2015 (As Amended)

25 June 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please find enclosed herewith intimation for investor meet on June 28, 2024.	
26 June 2024	Closure of Trading Window - Please find enclosed herewith intimation for the closure of trading window w.e./ Monday, July 1, 2024 until 48 hours from the declaration of Financial Results for the O.E. June 30, 2024	
01 July 2024	Shareholders Meeting 36Th AGM On Thursday, Jely 25, 2024 - Please find enclosed herewith Notice of 36th AGM of the Company.	
01 July 2024	Reg. 34 (1) Annual Report Please find enclosed herewith the Annual Report including Notice of 35th Annual General Meeting of the Company.	
02 July 2024	Announcement under Regulation 30 (LODR)-Newspaper Publication - Please find enclosed herewith News Paper Publication related to 35th AGM of the Company.	
	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please Ind enclosed herewith intimation for Investor Meet on Tuesday, July 09,	
04 July 2024	2024.	
15 July 2024	Compliances-Cartificate under Reg. 74 (6) of SEBI (DP) Regulations, 2018 - Please find enclosed herewith the certificate under regulation 74(6) of SEBI (DP) Regulations, 2018 for the Quarter Ended June 30, 2024.	
25 July 2024	Shareholder Meeting / Postal Ballot-Outcome of AGM - Please find the Outcome of the 35th Annual General Meeting of GPT Healthcare Limited Held on July 25, 2024.	
26 July 2024	Shareholder Meeting / Postal Balloh-Scrutinizar's Report - Please find the enclosed Voting Results and Scrutinizer Report on 35th AGM of the Company.	
07 August 2024	Baset Meeting Interaction for To Consider And Agrows The UN-Audited Frances IR Sease. Alrag With Report Of The Statutory Auditors Thereino Of The Company For The 15 Quarter Findu and 20, 2024 Of Heathance Lobas interaction BES that the meeting of the Board Of Decords of the Company Statistical 1398/2024. After alia, to consider and approve Un-audited Financial Results along with Report of the Statutory Auditors Interaction of the Company for the 1st quarter ended June 30, 2024.	
07 August 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please find enclosed herewith the invitation for the Earnings call for the 1st quarter ended June 30, 2024.	
13 August 2024	Board Meeting Outcome for Outcome Of The Board Meeting Held On August 13, 2024	
13 August 2024	Submission Of Un-Audited Financial Results For The Quarter Ended June 30, 2024	
13 August 2024	Amouncement under Regulation 30 (LODR)-Investor Presentation - Please find enclosed herewith the Investor Presentation for Q1 FY 2025.	
13 August 2024	Announcement under Regulation 30 (LODR)-Press Release / Media Release - Please find press release on the Quarterly Results for Q1 FY 2025.	
13 August 2024	Announcement under Regulation 30 (LODR)-Newspaper Publication - Rease find enclosed herewith News Paper Publication of Q1 FY 2025 Financial Results.	
14 August 2024	Announcement under Regulation 30 (LORR)-Analyst / Investor Meet - Outcome - Please find the Audio Link of Investor Call on the financial performance of the Company for the 1st quarter ended June 30, 2024.	
16 August 2024	Announcement under Regulation 30 (LODR)-Earnings Call Transcript - Please find enclosed herewith the transcript of the earnings call held on August 14, 2024 to discuss the Q1F/2025 result.	
22 August 2024	Amouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please lind the enclosed intimation for investor meet on August 27, 2024.	
29 August 2024	Amouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please lind enclosed intimation for investor meet on September 4, 2024.	
14 October 2024	Compliances-Certificate under Reg 74 (5) of SEBI (DP) Regulations, 2018 - Please find enclosed herewith the Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for the Q E September 30, 2024.	
04 November 2024	Board Meeting Intimation for Considering Inter Ala And Approving The Unaudited Financial Results (Bandalone) Of The Company For The 2Nd Quarter And Hall Year Ended On September 30, 2024 And To Declare Interim Dividend For The Financial Year 2024-25.	
06 November 2024	Announcement under Regulation 30 (LORR)-Analyst / Investor Meet - Intimation - Pease find enclosed herewith the invitation for the Earnings call for the 2nd quarter and hall year ended September 30, 2024.	
14 November 2024	Board Meeting Outcome for Q2FV25 Results - Please find the outcome of the Board Meeting dated November 14, 2024.	
14 November 2024	Results-Financial Results For 2Nd Quanter And Half Year Ended September 30, 2024 - Please find the Q2FY25 Results	
14 November 2024	Corporate Action-Board approves Dividend - Please find the intimation of Record date for the First interim Dividend for the FY 2024-25.	
14 November 2024	Amouncement under Regulation 30 (LODR)-Press Release / Media Release - Please find the Press Release on the Q2P/25 results.	
14 November 2024	Amouncement under Regulation 30 (LODR)-Investor Presentation - Please find the Investor Presentation for Q2P/25 Results.	
15 November 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome - Please find the Audio Recording of the Investor Call held on November 14, 2024.	
16 November 2024	Amouncement under Regulation 30 (LODR)-Newspaper Publication - Please find the News Paper Publication on Q2F1/25 Results and Notice of Record Date.	
Notes		

Notes: The Company meets Investors' Analysts' Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable. For further updates and information, please refer to the website of the Stock Exchanges i.e. www.beeinda.com

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIRM/RSD11/2012 dated January 10, 2012.

This information is gathered, inter-ails, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and/ or the National Stock Exchange of India Limited ("NSE" and logither with the BSE, the "Boock Exchanges") from time to time, price-volume data available on the website of the Sock Exchanges, other sources as disclosed herein and information / duritications provided by the Issuer.

Nothing in this information is intended by JM Financial to be construed as legal, regulatory, accounting tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are related, the user of this information may independently writly the accuracy of the information before taking any decision based on the above information.

Notwittstanding the above, JM Francial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained termin and shall not be liable in any manner for the same. Network JM Francial core any of the afflicters or derivative process of the information or data contained termin and shall not be liable in any manner for the same. Network JM Francial core any of the afflicters or derivative process of the information or data contained termin and shall not be liable in any manner for the same. Network JM Francial core and or of the same france and the information or data contained termin and shall not be liable in any manner for adding of control by approximations and completeness of the specific requirement. All Francial does not undertake to update the information contained termin except as required by applicable her or regulation.